Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Sagwa, Evans"'
Autor:
Wanyonyi, Eclayne Naswa1,2 (AUTHOR), Sagwa, Evans1 (AUTHOR), Banzimana, Stany1 (AUTHOR), Asingizwe, Domina1 (AUTHOR) adomina23@gmail.com
Publikováno v:
Journal of Pharmaceutical Policy & Practice. Dec2024, Vol. 17 Issue 1, p1-12. 12p.
Autor:
Sagwa, Evans Luvaha
Magister Public Health - MPH
Namibia is currently coping with a dual burden of human immunodeficiency (HIV) and HIV-associated tuberculosis (TB). In 2010, HIV prevalence was 18.8%, the TB case notification rate was 634 per 100,000 population, wh
Namibia is currently coping with a dual burden of human immunodeficiency (HIV) and HIV-associated tuberculosis (TB). In 2010, HIV prevalence was 18.8%, the TB case notification rate was 634 per 100,000 population, wh
Externí odkaz:
http://hdl.handle.net/11394/4625
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sagwa, Evans L.1 esagwa@gmail.com, Ruswa, Nunurai2, Mavhunga, Farai2, Rennie, Timothy3, Leufkens, Hubert G. M.1,4, Mantel-Teeuwisse, Aukje K.1
Publikováno v:
Patient Preference & Adherence. Nov2016, Vol. 10, p2369-2377. 9p.
Publikováno v:
Journal of Pharmaceutical Policy & Practice. 2014, Vol. 7 Issue 10, p7-14. 8p.
Introduction: Multidrug-resistant tuberculosis (MDR-TB), a growing global menace, is seriously undermining the previous successes made in the elimination of TB. MDR-TB treatment takes a long time, is complex, and is frequently associated with the occ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::29821cfe67a39e2a6310726abba414ce
https://dspace.library.uu.nl/handle/1874/353153
https://dspace.library.uu.nl/handle/1874/353153
Autor:
Sagwa, Evans L, Souverein, Patrick C, Ribeiro, Inês, Leufkens, Hubert G M, Mantel-Teeuwisse, Aukje K
PURPOSE: To evaluate the association between the use of streptomycin, amikacin, kanamycin and capreomycin in tuberculosis (TB) treatment and the pharmacovigilance reporting of ototoxicity (deafness or hearing loss, tinnitus and vertigo). Second, to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::c1a358fd223ab80fc2420a3cdcb6b6bc
https://dspace.library.uu.nl/handle/1874/356214
https://dspace.library.uu.nl/handle/1874/356214
Autor:
Sagwa, Evans1,2,3 esagwa@gmail.com, Mantel-Teeuwisse, Aukje Kaija2, Ruswa, Nunurai4, Musasa, Jean Paul5, Pal, Shanthi6, Dhliwayo, Panganai, van Wyk, Brian1
Publikováno v:
Southern Med Review. Jul2012, Vol. 5 Issue 1, p6-13. 8p. 1 Diagram, 3 Charts, 2 Graphs.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sagwa, Evans L, Ruswa, Nunurai, Mavhunga, Farai, Rennie, Timothy, Leufkens, Hubert G M, Mantel-Teeuwisse, Aukje K, Sub Gen. Pharmacoepi and Clinical Pharm, Sub Pharmacoepidemiology, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
BMC Pharmacology & Toxicology
BMC pharmacology & toxicology, 16(36). BioMed Central
BMC pharmacology & toxicology, 16(36). BioMed Central
Background Amikacin and kanamycin are mainly used for treating multidrug-resistant tuberculosis (MDR-TB), especially in developing countries where the burden of MDR-TB is highest. Their protracted use in MDR-TB treatment is known to cause dose-depend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e9f3d13ea660cdb651782358f578b7
https://doi.org/10.1186/s40360-015-0036-7
https://doi.org/10.1186/s40360-015-0036-7